Aardvark Therapeutics entered the second quarter of fiscal 2026 with two clinical programs advancing toward pivotal readouts and ended it with both programs paused, the lead asset under FDA clinical hold, and the company's strategic foundation fundamentally altered. The February voluntary pause across all four trials , HERO and OLE for ARD-101 in Prader-Willi syndrome, POWER and STRENGTH for ARD-201 in hypothalamic obesity , followed reversible cardiac observations in a healthy volunteer study. By May the FDA had placed ARD-101 on clinical hold with required human safety studies specified, and in June the company terminated the HERO and OLE trials entirely. This sequence transforms Aardvark from a clinical-stage biotech approaching binary catalysts into a company navigating a regulatory reset with an uncertain path forward for its primary asset.
The investment thesis now rests on three variables that determine whether Aardvark retains option value or becomes a stranded cash pile. First, the FDA's required safety studies for ARD-101 yield clean cardiac data; the agency has specified the exact studies needed, creating a defined but not guaranteed path to lifting the hold. Second, the company decide whether to pursue a redesigned ARD-101 trial in Prader-Willi syndrome or redirect resources entirely to ARD-201, which remains without a clinical hold but shares mechanistic similarities that could invite regulatory scrutiny. Third, the cash runway sustain operations through this indeterminate period; the $80.7 million in current assets at June 30, 2026 provides roughly 12-15 months at the current $36.5 million semi-annual burn rate, but any clinical restart or expanded safety package compresses that window.
The binary market implications are clear. Confirmation of a clean cardiac safety profile in the FDA-mandated studies, followed by a credible redesigned trial protocol for ARD-101, would restore the option value that underpinned the post-IPO valuation and could support a re-rating toward the $300-400 million enterprise value range implied by clinical-stage gut-brain peers. Failure to satisfy the FDA's requirements, or a determination that the cardiac signal represents a class effect extending to ARD-201, would collapse the equity toward liquidation value of the cash position minus wind-down costs. The market currently prices an intermediate probability, but the next six months of safety data readouts force resolution.